TD Cowen lowered the firm’s price target on HCA Healthcare (HCA) to $361 from $377 and keeps a Buy rating on the shares. The firm updated its modle following Q1 results while noting FY25 guidance was maintained given uncertainty around tariffs and broader policy environment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare: Balanced Risk/Reward Profile Justifies Hold Rating Amid Strong Performance and High Valuation
- HCA Healthcare: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- HCA Healthcare Reports Strong Q1 2025 Results
- HCA Healthcare Reports Strong Q1 Earnings Growth
- China weighs U.S. tariff exemptions, Alphabet reports Q1 beat: Morning Buzz